CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+2.75%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(-5.5%)
Cap. Flow
-$36.8M
Cap. Flow
% of AUM
-3.04%
Top 10 Holdings %
Top 10 Hldgs %
64.66%
Holding
46
New
2
Increased
11
Reduced
10
Closed
6
Top Buys
| 1 |
Relay Therapeutics
RLAY
|
$43.9M |
| 2 |
Intellia Therapeutics
NTLA
|
$36.5M |
| 3 |
GeneDx Holdings
WGS
|
$31.3M |
| 4 |
Structure Therapeutics
GPCR
|
$16.1M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$7.56M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$36.3M |
| 2 |
Illumina
ILMN
|
$25.6M |
| 3 |
MaxCyte
MXCT
|
$22.7M |
| 4 |
Sarepta Therapeutics
SRPT
|
$21.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$19M |
Sector Composition
| 1 | Healthcare | 99.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioLife Solutions
BLFS
$1.2B
| $165M | 13.57% | 7,571,535 +5,243 | +0.1% | +$114K |
|
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $160M | 13.17% | 1,160,000 -155,000 | -12% | -$21.4M |
|
|
3
Relay Therapeutics
RLAY
$619M
| $93.9M | 7.73% | 5,698,574 +2,667,926 | +88% | +$43.9M |
|
|
EQRX
4
DELISTED
EQRx, Inc. Common Stock
EQRX
| $76.7M | 6.32% | 39,527,669 | – | – |
|
|
5
Illumina
ILMN
$15.8B
| $64M | 5.27% | 275,000 -110,000 | -29% | -$25.6M |
|
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $54.1M | 4.46% | 270,000 -95,000 | -26% | -$19M |
|
|
7
Intellia Therapeutics
NTLA
$1.22B
| $47.5M | 3.91% | 1,275,000 +980,000 | +332% | +$36.5M |
|
8
Pliant Therapeutics
PLRX
$101M
| $44.6M | 3.67% | 1,675,000 | – | – |
|
9
Revolution Medicines
RVMD
$7.1B
| $39.2M | 3.23% | 1,810,000 -715,000 | -28% | -$15.5M |
|
10
Exact Sciences
EXAS
$8.98B
| $38.3M | 3.16% | 565,000 | – | – |
|
|
11
GeneDx Holdings
WGS
$3.72B
| $37.3M | 3.07% | 102,151,785 +85,714,285 | +521% | +$31.3M |
|
|
SLGC
12
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $32.1M | 2.65% | 12,604,275 | – | – |
|
|
VERV
13
DELISTED
Verve Therapeutics
VERV
| $30.6M | 2.52% | 2,120,571 -170,000 | -7% | -$2.45M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $30.1M | 2.48% | 670,000 -807,800 | -55% | -$36.3M |
|
15
Denali Therapeutics
DNLI
$2.23B
| $30M | 2.47% | 1,300,000 | – | – |
|
|
16
MaxCyte
MXCT
$148M
| $24.4M | 2.01% | 4,925,000 -4,580,000 | -48% | -$22.7M |
|
|
TSVT
17
DELISTED
2seventy bio
TSVT
| $20.6M | 1.7% | 2,023,913 +173,913 | +9% | +$1.77M |
|
18
AbCellera Biologics
ABCL
$1.25B
| $19M | 1.57% | 2,520,000 +250,000 | +11% | +$1.89M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $19M | 1.56% | 510,000 +35,000 | +7% | +$1.3M |
|
|
20
4D Molecular Therapeutics
FDMT
$288M
| $18.4M | 1.52% | 1,070,000 +440,000 | +70% | +$7.56M |
|
21
Beam Therapeutics
BEAM
$1.66B
| $17.5M | 1.44% | 570,000 +200,000 | +54% | +$6.12M |
|
22
Tenaya Therapeutics
TNYA
$184M
| $17.3M | 1.43% | 6,078,860 | – | – |
|
|
23
Structure Therapeutics
GPCR
$1.11B
| $16.1M | 1.33% | +677,017 | New | +$16.1M |
|
|
RXDX
24
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $16.1M | 1.33% | 150,000 | – | – |
|
25
Avidity Biosciences
RNA
$5.99B
| $13M | 1.07% | 850,000 | – | – |
|